Fallbericht
Early anti-C5 therapy in NMOSD: rationale and clinical evidence
Neurological Sciences · 2026-04 · 47 (4)
DOI: 10.1007/s10072-026-08952-2 ↗Kurz gefasst
Fallbericht in der Zeitschrift Neurological Sciences, online erschienen am 14.03.2026. Verfasst von Haruka Kido und 2 weiteren Autor:innen. Beteiligte Einrichtung: St. Mary's Hospital, Fukuoka, Japan. Hauptthemen laut MEDLINE: Neuromyelitis Optica, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 9 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Neuromyelitis OpticaAntibodies, Monoclonal, HumanizedHumansFemaleAdultAquaporin 4
Stichwörter der Autor:innen
50% hemolytic complement activity (CH50)Acute neuroinflammationAquaporin-4 antibodies (AQP4-IgG)Autoimmune astrocytopathyComplement C5 inhibitionEculizumabNeuromyelitis optica spectrum disorder (NMOSD)RavulizumabRescue therapy
Substanzen
Aquaporin 4Antibodies, Monoclonal, Humanizedeculizumab
Autor:innen und Institutionen
- St. Mary's Hospital, Fukuoka, Japan.
- Keio University Regenerative Medicine Research Center, Kanagawa, Japan. satoru_morimoto@keio.jp.
- Department of Cerebrovascular Medicine, Kyushu University, Fukuoka, Japan.
Zitieren
APA
Kido, H., Morimoto, S., & Matsuoka, M. (2026). Early anti-C5 therapy in NMOSD: rationale and clinical evidence. Neurological Sciences, 47(4). https://doi.org/10.1007/s10072-026-08952-2
Vancouver
Kido H, Morimoto S, Matsuoka M. Early anti-C5 therapy in NMOSD: rationale and clinical evidence. Neurological Sciences. 2026;47(4). doi:10.1007/s10072-026-08952-2
BibTeX
@article{Kido2026,
author = {Kido, Haruka and Morimoto, Satoru and Matsuoka, Mikiaki},
title = {Early anti-C5 therapy in NMOSD: rationale and clinical evidence},
journal = {Neurological Sciences},
year = {2026},
volume = {47},
number = {4},
doi = {10.1007/s10072-026-08952-2}
}
EUVIMED